Loading quotes...
Forecast
The analysts' average price target is €8.08 (+50.19%). The median is €8.18 (+52.04%).
| Buy |
Â
15 |
| Hold |
Â
27 |
| Sell |
Â
0 |
News Go to news feed
Teladoc Health appoints Michael Grasher as chief financial officer
Teladoc Health has appointed Michael Grasher as CFO, effective immediately. Grasher has more than 30 years of experience in the insurance and financial services sector, including over 12 years in CFO roles at companies such as IFG Companies, Fortegra and AMERISAFE, and he also spent many years in equity research. » More on de.investing.com
Teladoc Health appoints Mark V. Anquillare to the board of directors
Teladoc Health has appointed Mark V. Anquillare, former president and COO of Verisk Analytics, to its board of directors. He will serve on the audit and compensation committees and brings more than 30 years of experience in finance and leadership roles, including overseeing Verisk’s 2009 IPO. Anquillare also sits on several other boards; Teladoc Health provides virtual healthcare services through partnerships with insurers, employers and health systems. » More on de.investing.com
Teladoc reports revenue decline and cuts annual forecast – stock falls sharply
Teladoc reported Q2 revenue of $606.9 million, missing the analyst consensus of about $615 million, while adjusted EPS of -$0.21 beat expectations. Consumer segment BetterHelp shrank 12% to $212.6 million. For Q3 management expects revenue of $569–609 million and lowered the full-year guidance to $2.36–2.45 billion (previously $2.48–2.58 billion), which weighed heavily on the stock in premarket trading. CEO Chuck Divita cited provider capacity constraints as the reason for weaker revenue realization; over the past six months there have been only insider sales. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 531.8M | 0.81% |
| Gross profit | 545.08M | 45.56% |
| Net profit | -34.09M | 23.03% |
| EBITDA | -109.12M | 4,907.89% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €982.57M |
Number of shares | 181.68M |
52-week high/low | €8.51 - €3.79 |
| Dividends | No |
Beta | 2.13 |
P/E ratio | -6.34 |
PEG ratio | -0.38 |
P/B ratio | 0.86 |
P/S ratio | 0.46 |
Company profile
Teladoc Health, Inc. bietet virtuelle Gesundheitsdienste in den Vereinigten Staaten und international an. Das Unternehmen bietet ein Portfolio von Dienstleistungen und Lösungen für nicht dringende, episodische, chronische und komplizierte medizinische Erkrankungen, einschließlich Diabetes, Bluthochdruck, chronische Nierenerkrankungen, Krebs, Herzinsuffizienz und psychische Erkrankungen. Das Unternehmen bietet eine Reihe von Programmen und Dienstleistungen an, darunter Lösungen für die telemedizinische Grund- und Spezialversorgung, das Management chronischer Erkrankungen, medizinische Expertendienste, Lösungen für psychische Erkrankungen sowie Plattform- und Programmdienste. Das Unternehmen bedient Arbeitgeber, Gesundheitspläne, Krankenhäuser und Gesundheitssysteme, Versicherungs- und Finanzdienstleistungsunternehmen sowie Einzelmitglieder. Es bietet seine Produkte und Dienstleistungen unter den Marken Teladoc, Livongo und BetterHelp an. Das Unternehmen war früher als Teladoc, Inc. bekannt und änderte im August 2018 seinen Namen in Teladoc Health, Inc. Das Unternehmen wurde im Jahr 2002 gegründet und hat seinen Hauptsitz in Purchase, New York.
| Name | Teladoc Health |
| CEO | Charles Divita |
| Headquarters | New York,
ny USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| IPO | 06/30/2015 |
| Employees | 5,124 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | TDOC |
London Stock Exchange | 0LDR.L |
XETRA | 4LL.F |
Frankfurt | 4LL.F |
DĂĽsseldorf | 4LL.DU |
London | 0LDR.L |
SIX | 4LL.SW |
MĂĽnchen | 4LL.MU |
Discover assets
Shareholders of Teladoc Health also invest in the following assets